In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute's Toni Choueiri, MD, researchers ...

Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

In patients with advanced clear cell renal cell carcinoma (ccRCC), sitravatinib (tyrosine kinase inhibitor) has shown efficacy both alone and in combination with nivolumab (anti-PD-1). Here ...

A retrospective chart review compared the difference in outcomes between Black patients and White patients with advanced RCC for 3 first-line therapies.

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase I for Epithelial Ovarian Cancer.